DE2335827C2 - 2β-Hydroxy-3α-aminosteroide und Verfahren zu ihrer Herstellung - Google Patents
2β-Hydroxy-3α-aminosteroide und Verfahren zu ihrer HerstellungInfo
- Publication number
- DE2335827C2 DE2335827C2 DE2335827A DE2335827A DE2335827C2 DE 2335827 C2 DE2335827 C2 DE 2335827C2 DE 2335827 A DE2335827 A DE 2335827A DE 2335827 A DE2335827 A DE 2335827A DE 2335827 C2 DE2335827 C2 DE 2335827C2
- Authority
- DE
- Germany
- Prior art keywords
- hydroxy
- amino
- acid
- acetyloxy
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- QZLYKIGBANMMBK-UGCZWRCOSA-N 5α-Androstane Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 QZLYKIGBANMMBK-UGCZWRCOSA-N 0.000 claims description 7
- 150000003128 pregnanes Chemical class 0.000 claims description 7
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 239000003513 alkali Substances 0.000 claims description 4
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- 150000001540 azides Chemical class 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 3
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000003047 N-acetyl group Chemical group 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 239000000243 solution Substances 0.000 description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000007787 solid Substances 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 150000008065 acid anhydrides Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- VBTQNRFWXBXZQR-UHFFFAOYSA-N n-bromoacetamide Chemical compound CC(=O)NBr VBTQNRFWXBXZQR-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000001302 tertiary amino group Chemical group 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NDDAQHROMJDMKS-XFYXLWKMSA-N [(2s,3s,5s,8r,9s,10s,13s,14s)-2-hydroxy-10,13-dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl]azanium;chloride Chemical compound Cl.C1[C@H](N)[C@@H](O)C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 NDDAQHROMJDMKS-XFYXLWKMSA-N 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003863 metallic catalyst Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB3311272A GB1439605A (en) | 1972-07-14 | 1972-07-14 | 2beta-hydroxy-3-alpha-amino-steroids and derivatives thereof and the processes for their preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2335827A1 DE2335827A1 (de) | 1974-01-31 |
| DE2335827C2 true DE2335827C2 (de) | 1984-09-20 |
Family
ID=10348720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2335827A Expired DE2335827C2 (de) | 1972-07-14 | 1973-07-13 | 2β-Hydroxy-3α-aminosteroide und Verfahren zu ihrer Herstellung |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US3862196A (OSRAM) |
| JP (1) | JPS5752360B2 (OSRAM) |
| BE (1) | BE802336A (OSRAM) |
| CA (1) | CA1033355A (OSRAM) |
| CH (1) | CH603690A5 (OSRAM) |
| DE (1) | DE2335827C2 (OSRAM) |
| DK (1) | DK131575B (OSRAM) |
| ES (1) | ES416879A1 (OSRAM) |
| FI (1) | FI53132C (OSRAM) |
| FR (1) | FR2192837B1 (OSRAM) |
| GB (1) | GB1439605A (OSRAM) |
| HU (1) | HU170929B (OSRAM) |
| IE (1) | IE37876B1 (OSRAM) |
| NL (1) | NL7309592A (OSRAM) |
| PH (1) | PH10088A (OSRAM) |
| SE (1) | SE399271B (OSRAM) |
| ZA (1) | ZA734461B (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3239823A1 (de) * | 1981-10-27 | 1983-05-05 | Roussel-Uclaf, 75007 Paris | Neue 3-amino-pregn-5-en-derivate, deren salze, deren herstellung, deren verwendung als arzneimittel und die sie enthaltenden zusammensetzungen |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2030569A (en) * | 1978-10-03 | 1980-04-10 | Akzo Nv | Amino hydroxy steroids and derivatives thereof |
| ZA81348B (en) * | 1980-01-30 | 1982-02-24 | Akzo Nv | Novel 17-amino-16-hydroxy steroids of the androstane and oestrane series and derivatives thereof,processes for their preparation and pharmaceutical compositions |
| NZ197725A (en) * | 1980-07-16 | 1984-11-09 | Glaxo Group Ltd | 11-alpha-aminoandrostanes and pharmaceutical compositions |
| AU7288081A (en) * | 1980-07-16 | 1982-01-21 | Glaxo Group Limited | 11alpha-amino-androstanes |
| FR2494696A1 (fr) * | 1980-11-21 | 1982-05-28 | Roussel Uclaf | Nouveau procede de preparation de steroides 3-amines et leurs sels |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1108563A (en) * | 1963-11-14 | 1968-04-03 | Organon Labor Ltd | 3ª‡-amino steroids and the preparation thereof |
| BE657319A (OSRAM) * | 1964-01-02 | |||
| US3304302A (en) * | 1965-01-04 | 1967-02-14 | Sterling Drug Inc | 3-amino-2-oxo steroids |
| US3511859A (en) * | 1968-04-23 | 1970-05-12 | Searle & Co | 2,3-diazido/diamino-5alpha-androstan-17-ones and derivatives thereof |
-
1972
- 1972-07-14 GB GB3311272A patent/GB1439605A/en not_active Expired
-
1973
- 1973-07-02 ZA ZA734461A patent/ZA734461B/xx unknown
- 1973-07-04 IE IE1120/73A patent/IE37876B1/xx unknown
- 1973-07-10 DK DK382173AA patent/DK131575B/da unknown
- 1973-07-10 NL NL7309592A patent/NL7309592A/xx not_active Application Discontinuation
- 1973-07-10 US US377977A patent/US3862196A/en not_active Expired - Lifetime
- 1973-07-10 CA CA176,050A patent/CA1033355A/en not_active Expired
- 1973-07-11 FI FI2208/73A patent/FI53132C/fi active
- 1973-07-12 PH PH14818A patent/PH10088A/en unknown
- 1973-07-12 HU HU73AO00000371A patent/HU170929B/hu unknown
- 1973-07-13 ES ES416879A patent/ES416879A1/es not_active Expired
- 1973-07-13 BE BE133476A patent/BE802336A/xx not_active IP Right Cessation
- 1973-07-13 JP JP48079220A patent/JPS5752360B2/ja not_active Expired
- 1973-07-13 SE SE7309860A patent/SE399271B/xx unknown
- 1973-07-13 DE DE2335827A patent/DE2335827C2/de not_active Expired
- 1973-07-13 CH CH1025573A patent/CH603690A5/xx not_active IP Right Cessation
- 1973-07-13 FR FR7325904A patent/FR2192837B1/fr not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3239823A1 (de) * | 1981-10-27 | 1983-05-05 | Roussel-Uclaf, 75007 Paris | Neue 3-amino-pregn-5-en-derivate, deren salze, deren herstellung, deren verwendung als arzneimittel und die sie enthaltenden zusammensetzungen |
Also Published As
| Publication number | Publication date |
|---|---|
| HU170929B (hu) | 1977-10-28 |
| ES416879A1 (es) | 1976-02-16 |
| BE802336A (fr) | 1974-01-14 |
| US3862196A (en) | 1975-01-21 |
| PH10088A (en) | 1976-08-13 |
| IE37876L (en) | 1974-01-14 |
| JPS4985059A (OSRAM) | 1974-08-15 |
| JPS5752360B2 (OSRAM) | 1982-11-06 |
| SE399271B (sv) | 1978-02-06 |
| DK131575C (OSRAM) | 1975-12-29 |
| FI53132B (OSRAM) | 1977-10-31 |
| FR2192837B1 (OSRAM) | 1977-04-15 |
| FR2192837A1 (OSRAM) | 1974-02-15 |
| GB1439605A (en) | 1976-06-16 |
| FI53132C (OSRAM) | 1978-02-10 |
| AU5774173A (en) | 1975-01-09 |
| DK131575B (da) | 1975-06-04 |
| CA1033355A (en) | 1978-06-20 |
| IE37876B1 (en) | 1977-11-09 |
| CH603690A5 (OSRAM) | 1978-08-31 |
| ZA734461B (en) | 1974-06-26 |
| DE2335827A1 (de) | 1974-01-31 |
| NL7309592A (OSRAM) | 1974-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE965036C (de) | Verfahren zur Herstellung von p-(Bis-2-chloraethyl-amino)-ª-phenyl-alanin | |
| CH633264A5 (de) | N-alkylpiperidin-derivate. | |
| DE2031724A1 (de) | Neue Röntgenkontrastmittel | |
| DE1593272A1 (de) | Verfahren zur Herstellung von Halogen-Tetracyclinen | |
| DE1643296C3 (de) | l-Aryl-2-alkylaminoäthanole und deren physiologisch verträgliche Säureadditionssalze, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel | |
| DE2335827C2 (de) | 2β-Hydroxy-3α-aminosteroide und Verfahren zu ihrer Herstellung | |
| DE2629228C2 (de) | Jodierte Isophthalamsäure-Derivate Verfahren zu deren Herstellung sowie deren Verwendung | |
| DE1793841B1 (de) | trans-4-Aminomethylcyclohexan-1-carbonsaeure und Verfahren zur Herstellung | |
| DE2346122C2 (de) | 6-Dihydroxyäthyl-2,4,7-trioxo-8-D-ribitylpteridin sowie Verfahren zu seiner Herstellung | |
| DE1962757B2 (de) | Evomonosid-Derivate, Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittel | |
| DE2013032C3 (de) | 3-Amino-cardenolide, Verfahren zu ihrer Herstellung sowie deren Verwendung bei der Bekämpfung von Herz- und Kreislauf-Krankheiten | |
| DE1274100B (de) | Verfahren zur Herstellung von 1, 6-Dibrom-1, 6-didesoxydulcit | |
| DE2757057A1 (de) | Daunomycinderivate, verfahren zu ihrer herstellung und ihre verwendung | |
| DE1912944A1 (de) | Cycloalkanochinolonderivate und Verfahren zu deren Herstellung | |
| DE2738498A1 (de) | Neue nitrosoharnstoffderivate | |
| DE2735458A1 (de) | Neue imidazolderivate | |
| AT344335B (de) | Verfahren zur herstellung von neuen derivaten des vitamins d2 bzw. d3 und des epi-vitamins d2 bzw. d3 | |
| DE2549863C3 (de) | Pyridoxyliden-p-amino-benzoesäurederivate, deren Herstellung und Verwendung | |
| DE1235929B (de) | Verfahren zur Herstellung von 2-(2'-Pyrazinyl)-benzimidazol und seinen Salzen | |
| CH634835A5 (de) | Verfahren zur herstellung von neuen benzodiazepinderivaten. | |
| DE1943901C3 (de) | Cardenolid-3-[2', 3' - didesoxyglykoside] und Verfahren zu ihrer Herstellung, sowie Verwendung dieser Verbindungen zur Bekämpfung von Herzkrankheiten | |
| DE2560038C2 (de) | H2-Chloräthyl)-1 nitroso-3-(hydroxycyclohexyl)harnstoffe, dieselben enthaltende Arzneimittel und Verfahren zur Herstellung der ersteren | |
| DE3306505C2 (de) | 4-Desmethoxy-13-dihydro-daunorubicin, Verfahren zu dessen Herstellung und diese Verbindung enthaltende Arzneimittel | |
| AT311553B (de) | Verfahren zur Herstellung von Antibiotika | |
| DE1568222C (de) | 3,4-Diäther des Helveticosids und Helveticosols und Verfahren zu deren Herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OD | Request for examination | ||
| 8125 | Change of the main classification |
Ipc: C07J 41/00 |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |